These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37562518)

  • 1. Unmet needs and future directions in hypertrophic cardiomyopathy.
    Kaur S; Desai M
    Prog Cardiovasc Dis; 2023; 80():1-7. PubMed ID: 37562518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypertrophic cardiomyopathy: the future of treatment.
    Tuohy CV; Kaul S; Song HK; Nazer B; Heitner SB
    Eur J Heart Fail; 2020 Feb; 22(2):228-240. PubMed ID: 31919938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contemporary Therapies and Future Directions in the Management of Hypertrophic Cardiomyopathy.
    Packard E; de Feria A; Peshin S; Reza N; Owens AT
    Cardiol Ther; 2022 Dec; 11(4):491-507. PubMed ID: 36243823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unmet needs in the treatment of hypertrophic cardiomyopathy.
    Hutt E; Nissen SE; Desai MY
    Future Cardiol; 2021 Oct; 17(7):1261-1267. PubMed ID: 33960215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Cardiac Myosin Inhibitor Therapy for Hypertrophic Cardiomyopathy in Adults: A Contemporary Review.
    Kalinski JK; Xu B; Boyd R; Tasseff N; Rutkowski K; Ospina S; Smedira N; Thamilarasan M; Popovic ZB; Desai MY
    Am J Cardiovasc Drugs; 2024 Jul; ():. PubMed ID: 39030459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy and Future Directions.
    Dong T; Alencherry B; Ospina S; Desai MY
    Drug Des Devel Ther; 2023; 17():1097-1106. PubMed ID: 37064432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypertrophic Cardiomyopathy 2020.
    Kogut J; Popjes ED
    Curr Cardiol Rep; 2020 Oct; 22(11):154. PubMed ID: 33025145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Advantages of New Multimodality Imaging in Choosing the Optimal Management Strategy for Patients with Hypertrophic Cardiomyopathy.
    Anghel L; Stătescu C; Șerban IL; Mărănducă MA; Butcovan D; Clement A; Bostan M; Sascău R
    Diagnostics (Basel); 2020 Sep; 10(9):. PubMed ID: 32961665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An evaluation of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults.
    Dong T; Nissen S; Ospina S; Desai MY
    Expert Rev Cardiovasc Ther; 2023 Jan; 21(1):5-13. PubMed ID: 36522857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives.
    Maron BJ; Maron MS; Semsarian C
    J Am Coll Cardiol; 2012 Aug; 60(8):705-15. PubMed ID: 22796258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypertrophic cardiomyopathy: an up-to-date snapshot of the clinical drug development pipeline.
    Tamargo J; Tamargo M; Caballero R
    Expert Opin Investig Drugs; 2022 Oct; 31(10):1027-1052. PubMed ID: 36062808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Approach Targeting the Complex Pathophysiology of Hypertrophic Cardiomyopathy: The Impact of Late Sodium Current Inhibition on Exercise Capacity in Subjects with Symptomatic Hypertrophic Cardiomyopathy (LIBERTY-HCM) Trial.
    Olivotto I; Hellawell JL; Farzaneh-Far R; Blair C; Coppini R; Myers J; Belardinelli L; Maron MS
    Circ Heart Fail; 2016 Mar; 9(3):e002764. PubMed ID: 26915375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypertrophic cardiomyopathy: a systematic review.
    Maron BJ
    JAMA; 2002 Mar; 287(10):1308-20. PubMed ID: 11886323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypertrophic Cardiomyopathy: Diverse Pathophysiology Revealed by Genetic Research, Toward Future Therapy.
    Hayashi T
    Keio J Med; 2020 Dec; 69(4):77-87. PubMed ID: 32224552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Familial Hypertrophic Cardiomyopathy: Diagnosis and Management.
    Litt MJ; Ali A; Reza N
    Vasc Health Risk Manag; 2023; 19():211-221. PubMed ID: 37050929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mavacamten: a novel small molecule modulator of β-cardiac myosin for treatment of hypertrophic cardiomyopathy.
    Tower-Rader A; Ramchand J; Nissen SE; Desai MY
    Expert Opin Investig Drugs; 2020 Nov; 29(11):1171-1178. PubMed ID: 32897741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospects for remodeling the hypertrophic heart with myosin modulators.
    Sewanan LR; Shimada YJ
    Front Cardiovasc Med; 2022; 9():1051564. PubMed ID: 36330009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treating a Structural Heart Disease Using a Non-structural Approach: Role of Cardiac Pacing in Hypertrophic Cardiomyopathy.
    Albano BB; Fadreguilan EC; Chua JM; Ho J; Medrano AB
    Cardiol Res; 2017 Feb; 8(1):20-25. PubMed ID: 28275421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-modality management of hypertrophic cardiomyopathy.
    Rao SJ; Iqbal SB; Kanwal AS; Aronow WS; Naidu SS
    Hosp Pract (1995); 2023 Feb; 51(1):2-11. PubMed ID: 36598161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypertrophic cardiomyopathy: Mutations to mechanisms to therapies.
    Kawana M; Spudich JA; Ruppel KM
    Front Physiol; 2022; 13():975076. PubMed ID: 36225299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.